Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted therapy with kinase inhibitors in aggressive endocrine tumors.
Marotta V, Franzese MD, Del Prete M, Chiofalo MG, Ramundo V, Esposito R, Marciello F, Pezzullo L, Carratù A, Vitale M, Colao A, Faggiano A. Marotta V, et al. Among authors: ramundo v. Expert Opin Pharmacother. 2013 Jun;14(9):1187-203. doi: 10.1517/14656566.2013.796931. Expert Opin Pharmacother. 2013. PMID: 23675883 Review.
Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A. Fiore F, et al. Among authors: ramundo v. Endocrine. 2014 Sep;47(1):177-82. doi: 10.1007/s12020-013-0130-9. Epub 2014 Jan 3. Endocrine. 2014. PMID: 24385266
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
Circelli L, Sciammarella C, Guadagno E, Tafuto S, del Basso de Caro M, Botti G, Pezzullo L, Aria M, Ramundo V, Tatangelo F, Losito NS, Ieranò C, D'Alterio C, Izzo F, Ciliberto G, Colao A, Faggiano A, Scala S. Circelli L, et al. Among authors: ramundo v. Oncotarget. 2016 Apr 5;7(14):18865-75. doi: 10.18632/oncotarget.7738. Oncotarget. 2016. PMID: 26934559 Free PMC article.
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A; Multidisciplinary Group for Neuroendocrine Tumors of Naples. Ramundo V, et al. Clin Endocrinol (Oxf). 2014 Jun;80(6):850-5. doi: 10.1111/cen.12411. Epub 2014 Feb 19. Clin Endocrinol (Oxf). 2014. PMID: 24443791
Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A. Faggiano A, et al. Among authors: ramundo v. Clin Endocrinol (Oxf). 2008 Nov;69(5):756-62. doi: 10.1111/j.1365-2265.2008.03301.x. Epub 2008 May 14. Clin Endocrinol (Oxf). 2008. PMID: 18485119 Clinical Trial.
Limitations of Chromogranin A in clinical practice.
Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G, Vitale M, Colao A, Faggiano A. Marotta V, et al. Among authors: ramundo v. Biomarkers. 2012 Mar;17(2):186-91. doi: 10.3109/1354750X.2012.654511. Epub 2012 Feb 6. Biomarkers. 2012. PMID: 22303881
61 results